Explaining Tumor-Infiltrating Lymphocytes As a Cancer Treatment
FDA Greenlights Lifileucel for Unresectable, Metastatic Melanoma Via Accelerated Approval
One of the challenges of cancer is the immune system does not often recognize cancer cells as diseased or dangerous. Cancer cells are mutated versions of the body’s natural cells, and they possess characteristics similar to healthy cells, which tricks the immune system.
Some immune system cells can recognize cancer cells as diseased, but the tumor microenvironment can prevent immune cells from doing much damage.
A few immune cells sometimes are successful in bypassing the tumor microenvironment and penetrating the tumor wall, which means they’ve infiltrated into the disease and began fighting and killing tumors. These are called tumor-infiltrating lymphocytes, and they can be T cells or B cells.
They’re also candidates for transformation into cancer therapy.
Tumor-infiltrating lymphocyte (TIL) therapy is a type of
TIL therapy involves removing these tumor-infiltrating cells and amplifying them to create billions more, all with the same original and successful anti-cancer traits. Scientists remove TILs directly from the tumor, ensuring that they collect proficient immune cells for multiplication.
Using TIL therapy to treat cancer
Since TIL therapy uses cells that are already gaining ground in the battle with cancer, this type of cell therapy holds potential against solid tumors.
There have also been several studies and clinical trials using TIL therapy for melanoma specifically, with positive results and hope for future research advancements.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025
- Duchenne Action Month 2025: Looking Back at News and Expert Insights
September 14th 2025
- CGTLive®’s Weekly Rewind – September 12, 2025
September 12th 2025